Wipfli Financial Advisors’s Akebia Therapeutics AKBA Stock Holding History

Wipfli Financial Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$63K	Buy	+200,000	New	+$78.5K	﹤0.01%	958

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wipfli Financial Advisors's AKBA Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Akebia Therapeutics (AKBA) in Q3 2022: 200,000 shares worth $63K. The stake represents ﹤0.01% of the portfolio and ranks #958 among its holdings.

90 funds tracked by Wall St. Rank hold AKBA as of Q3 2022.

Wipfli Financial Advisors held 200,000 shares of Akebia Therapeutics worth $63K as of Q3 2022.
Akebia Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
Akebia Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #958 holding.
90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.